Showing 1–25 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Harris RC, Sumner T, Knight GM, Evans T, Cardenas V, et al.
…d largest number of cases worldwide. New tools, such as new vaccines, are needed to meet WHO tuberculosis goals. Tuberculosis vaccine development strategies mostly target infants or adolescents, but given China's ageing epidemic, vaccinating older people might be important. We mo…
Faust L, Schreiber Y, Bocking N
Background Bacille Calmette-Guérin (BCG) vaccination against tuberculosis (TB) is widespread in high-TB-burden countries, however, BCG vaccination policies in low-burden countries vary. Considering the uncertainties surrounding BCG efficacy and the lower likelihood of TB exposure…
Rakshit S, Adiga V, Ahmed A, Parthiban C, Chetan Kumar N, et al.
… adaptive immune responses to current and emerging COVID-19 vaccines.
Ullah I, Bibi S, Ul Haq I, Safia, Ullah K, et al.
…unogenicity and safety of the M72/AS01 E and MVA85A subunit vaccines. The M72/AS01 E is a novel peptide-based vaccine currently in progress, which may increase the protection level against TB infection. The MVA85A was a viral vector-based TB subunit vaccine being used in the clin…
Prabowo SA, Painter H, Zelmer A, Smith SG, Seifert K, et al.
Tuberculosis (TB) is a major global health problem and there is a dire need for an improved treatment. A strategy to combine vaccination with drug treatment, termed therapeutic vaccination, is expected to provide benefit in shortening treatment duration and augmenting treatment s…
Brett K, Severn M
… general use, and it is one of the most widely administered vaccines. Nevertheless, there are still some questions with regards to the effectiveness of the BCG vaccine, particularly, the duration of the effect, and the ability to protect against pulmonary TB in adults. A global r…
Yang Y, Xue Y, Wang X, Wang L, Wang J, et al.
…aluate the biological characteristics and immunogenicity of vaccines can improve the efficiency of vaccine development. Objectives To evaluate the immunogenicity of TB vaccine W541 and to explore the application of bioinformatics technology in TB vaccine research. Methods This st…
Nayak SS, Sethi G, Ramadas K
Tuberculosis is an airborne transmissible disease caused by Mycobacterium tuberculosis that infects millions of lives worldwide. There is still no single comprehensive therapy or preventative available for the lethal illness. Currently, the available vaccine, BCG is ineffectual i…
Gopalaswamy R, Subbian S
…d conditions, such as HIV infection, is questionable. Novel vaccines, including recombinant BCG (rBCG), were developed to improve BCG's efficacy and use as an alternative to BCG in a vulnerable population. The first-generation rBCG vaccines had different Mtb antigens and were tes…
Billeskov R, Lindenstrøm T, Woodworth J, Vilaplana C, Cardona PJ, et al.
Mycobacterium tuberculosis (Mtb), the etiologic agent of tuberculosis (TB), causes 1.8M deaths annually. The current vaccine, BCG, has failed to eradicate TB leaving 25% of the world's population with latent Mtb infection (LTBI), and 5-10% of these people will reactivate and deve…
Ji Z, Jian M, Chen T, Luo L, Li L, et al.
Background: Currently, there is no tuberculosis (TB) vaccine recommended for use in latent TB infections and healthy adults. M72/AS01 E is a new peptide vaccine currently under development, which may improve protection against TB disease. This vaccine has been investigated in sev…
Yuta Norimatsu, Kazuma Ito, Takayuki Shiomi, Katsunori Fujii, Makoto Sugaya
…re rare reports of psoriasis-like skin rash caused by these vaccines. The mechanism by which psoriasis-like skin rash develops after BCG vaccination is unknown, but it has been suggested that it may occur when BCG vaccination is given to patients infected with tuberculosis. Here,…
Banurekha VV, Padmapriyadarsini C, Bhargava S, Sachdeva K
…in young children but not in adolescents and adults. New TB vaccines are the need of the hour. The TB vaccine development pipeline in the past years is encouraging with newer TB vaccines in clinical trials in humans. The focus of the newer TB vaccine is the prevention of infectio…
Nakken O, Aarseth JH, Wergeland S, Stigum H, Meyer HE, et al.
Introduction Bacillus Calmette-Guérin (BCG) vaccination induces long-lasting effects on the adaptive and innate immune systems and prevents development of experimental autoimmune encephalomyelitis and possibly also inflammatory disease activity in multiple sclerosis (MS). Objecti…
Fu H, Lin HH, Hallett TB, Arinaminpathy N
Background Bacillus Calmette-Guérin (BCG) vaccination is a widely-used public health intervention for tuberculosis (TB) control. In Taiwan, like other intermediate TB burden settings, steadily declining TB incidence raises important questions on whether universal BCG vaccination …
Sethi G, Varghese RP, Lakra AK, Nayak SS, Krishna R, et al.
… Therefore, there is a pressing need to find novel and safe vaccines that provide robust immune defense and have various applications. Vaccines that combine epitopes from multiple candidate proteins have been shown to boost immunity against Mtb infection. This study applies an im…
Buyun Xu, Mengjuan Yuan, Lisa Yang, Lan Huang, Jingxin Li, et al.
…e is an urgent need to develop more effective preventive TB vaccines. Currently, preventive TB vaccines under clinical investigation globally include live attenuated vaccines, recombinant subunit vaccines, viral vector vaccines, and mRNA vaccines. This article reviews and summari…
Flores-Valdez MA, Kupz A, Subbian S
…ly needed to improve global TB control measures. Since live vaccines elicit a broader immune response and do not require an adjuvant, developing recombinant BCG (rBCG) vaccine candidates have received significant attention as a potential replacement for the currently approved BCG…
Whitlow E, Mustafa AS, Hanif SNM
…aches, e.g., whole-cell organisms, subunit, and recombinant vaccines are currently being explored for safer and more efficacious TB vaccines than BCG. These approaches have been successful in developing a large number of vaccine candidates included in the TB vaccine pipeline and …
Wilson L, Gracie L, Kidy F, Thomas GN, Nirantharakumar K, et al.
Background Tuberculosis (TB) remains a leading cause of death worldwide, with 98% of cases occurring in low- and middle-income countries (LMICs). The only vaccine licenced for the prevention of TB has limited protection for adolescents, adults and vulnerable populations. A safe a…
Kumari R S, Sethi G, Krishna R
The etiological agent of tuberculosis (TB), Mycobacterium tuberculosis , is a deadly pathogen that adapts to thrive within the host. Since 2020, the COVID-19 pandemic has had colossal health, societal, and economic consequences, which have affected the reporting of new incidences…
Kashangura R, Jullien S, Garner P, Johnson S
Background Tuberculosis causes more deaths than any other infectious disease globally. Bacillus Calmette-Guérin (BCG) is the only available vaccine, but protection is incomplete and variable. The modified Vaccinia Ankara virus expressing antigen 85A (MVA85A) is a viral vector vac…
Rahali N, Bahloul C
… vaccination can help against immune escapes of the current vaccines.
Maurya SK, Aqdas M, Das DK, Singh S, Nadeem S, et al.
Background Approximately 80% - 90% of individuals infected with latent Mycobacterium tuberculosis (Mtb) remain protected throughout their life-span. The release of unique, latent-phase antigens are known to have a protective role in the immune response against Mtb. Although the B…
Yousefi Avarvand A, Khademi F, Tafaghodi M, Ahmadipour Z, Moradi B, et al.
…fections in adults. Furthermore, recently developed subunit vaccines, which are in various stages of clinical trials, are all prophylactic vaccines based on proteins expressed in replicating stage of M. tuberculosis and they are not preventive of reactivation of latent TB infecti…